EPITHELIAL BARRIER DISORDERS AS A COMMON PATHOGENETIC MECHANISM OF CHRONIC BRONCHOPULMONARY DISEASES AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE

  2. 2026
  3. EPITHELIAL BARRIER DISORDERS AS A COMMON PATHOGENETIC MECHANISM OF CHRONIC BRONCHOPULMONARY DISEASES AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE

Pivtorak K. V., Shevchuk T. V.

EPITHELIAL BARRIER DISORDERS AS A COMMON PATHOGENETIC MECHANISM OF CHRONIC BRONCHOPULMONARY DISEASES AND METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE

Show/Download

About the author:

Pivtorak K. V., Shevchuk T. V.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

Epithelial barrier disruption has been considered a universal mechanism for the development of chronic inflam matory and metabolic diseases in the last decade. The increasing prevalence of chronic obstructive pulmonary dis ease, bronchial asthma, and metabolic-associated steatohepatitis disease has prompted the search for common pathogenetic links that could explain their comorbidity and systemic nature of the course. One of these links is the dysfunction of tight junctions of the respiratory tract and intestinal epithelium, which contributes to increased per meability, translocation of microbial components, and maintenance of chronic systemic inflammation. Analysis of studies over the past 10 years demonstrates significant progress in understanding the role of the microbiota and the gut–lung–liver axis. Modern meta-analyses confirm the presence of increased intestinal permeability in IBD, and experimental studies prove the influence of dysbiosis on the immune response in the lungs. Studies of molecular mechanisms of regulation of tight junctions (claudins, occludin, zonulin), TLR4-dependent signaling and NF-κB activation have deepened the understanding of the relationship between barrier dysfunction and the progression of inflammation. At the same time, the mechanisms of interorgan communication, the role of epigenetic changes in the epithelium, as well as the possibilities of targeted correction of barrier permeability as a universal therapeutic strat egy for combined lung and liver pathology remain insufficiently understood. The aim of the work is to systematize modern scientific data on the role of epithelial barrier dysfunction in the pathogenesis of chronic bronchopulmonary diseases and metabolic-associated steatotic liver disease. The study is aimed at analyzing common molecular mech anisms and interorgan relationships within the “gut–lung–liver” axis. The obtained generalizations are intended to substantiate the prospects for the development of personalized approaches to diagnosis and treatment.

Tags:

bronchial asthma, COPD, epithelial permeability, MASLD, microbiota

Bibliography:

  1. Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol. 2025;10(6):573-592. DOI: 10.1016/S2468-1253(24)00390-X.
  2. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14(3):141 53. DOI: 10.1038/nri3608.
  3. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol. 2010;5:119-44. DOI: 10.1146/ annurev.pathol. 4.110807.092135.
  4. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, et al. Intestinal permeability – a new target for disease preven tion and therapy. BMC Gastroenterol. 2014;14:189. DOI: 10.1186/s12876-014-0189-7.
  5. Mohammadi-Kordkhayli M, Mousavi MJ, Camara-Lemarroy CR, Noorbakhsh F, Saboor-Yaraghi AA. Elucidating the significance of zonu lin in the pathogenesis of chronic inflammatory disorders: emphasis on intestinal barrier function and tight junction regulation. Curr Med Chem. 2025;32(30):6547-6562. DOI: 10.2174/0109298673335863240829060545.
  6. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57 71. DOI: 10.1146/annurev.pharmtox.48.113006.094742.
  7. De Munck TJI, Xu P, Verwijs HJA, Masclee AAM, Jonkers D, Verbeek J, et al. Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2020;40(12):2906-16. DOI: 10.1111/liv.14696.
  8. Liu L, Yin M, Gao J, Yu C, Lin J, Wu A, et al. Intestinal barrier function in the pathogenesis of nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2023;11(2):452-8. DOI: 10.14218/JCTH.2022.00089.
  9. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412-25. DOI: 10.1038/nrgastro.2016.85.
  10. Long C, Zhou X, Xia F, Zhou B. Intestinal barrier dysfunction and gut microbiota in non-alcoholic fatty liver disease: assessment, mecha nisms, and therapeutic considerations. Biology (Basel). 2024;13(4):243. DOI: 10.3390/biology13040243.
  11. Budden KF, Gellatly SL, Wood DL, Cooper MA, Morrison M, Hugenholtz P, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol. 2017;15(1):55-63. DOI: 10.1038/nrmicro.2016.142.
  12. Ma YY, Li L, Yu CH, Shen Z, Chen LH, Li YM. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroen terol. 2013;19(40):6911-8. DOI: 10.3748/wjg.v19.i40.6911.
  13. Moon HG, Kim SJ, Jeong JJ, Han SS, Jarjour NN, Lee H, et al. Airway epithelial cell-derived colony stimulating factor-1 promotes allergen sensitization. Immunity. 2018;49:275-87.e5.
  14. Staudt MR, Buro-Auriemma LJ, Walters MS, Salit J, Vincent T, Shaykhiev R, et al. Airway basal stem/progenitor cells have diminished capacity to regenerate airway epithelium in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190:955-8. DOI: 10.1164/rccm.201406-1167LE.
  15. Crystal RG. Airway basal cells. The “smoking gun” of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190:1355 62. DOI: 10.1164/rccm.201408-1492PP.
  16. Gohy S, Carlier FM, Fregimilicka C, Detry B, Lecocq M, Ladjemi MZ, et al. Altered generation of ciliated cells in chronic obstructive pulmonary disease. Sci Rep. 2019;9:17963.
  17. Chen G, Korfhagen TR, Karp CL, Impey S, Xu Y, Randell SH, et al. Foxa3 induces goblet cell metaplasia and inhibits innate antiviral immunity. Am J Respir Crit Care Med. 2014;189:301-13. DOI: 10.1164/rccm.201306-1181OC.
  18. Perotin JM, Coraux C, Lagonotte E, Birembaut P, Delepine G, Polette M, et al. Alteration of primary cilia in COPD. Eur Respir J. 2018;52:1800122. DOI: 10.1183/13993003.00122-2018.
  19. Yaghi A, Dolovich MB. Airway epithelial cell cilia and obstructive lung disease. Cells. 2016;5:40. DOI: 10.3390/cells5040040.
  20. Yeung-Luk BH, et al. Epigenetic reprogramming drives epithelial disruption in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2024;70(3):165-177.
  21. Burke H, Leonardi-Bee J, Hashim A, Pine-Abata H, Chen Y, Cook DG, et al. Prenatal and passive smoke exposure and incidence of asthma and wheeze: systematic review and meta-analysis. Pediatrics. 2012;129(4):735-44. DOI: 10.1542/peds.2011-2196.
  22. Jin Y, Seiber EE, Ferketich AK. Secondhand smoke and asthma: what are the effects on healthcare utilization among children? Prev Med. 2013;57(2):125-8. DOI: 10.1016/j.ypmed.2013.04.009.
  23. Sun YB, Liu M, Fan XS, Zhou LP, Li MW, Hu FY, et al. Effects of cigarette smoke on the aggravation of ovalbumin-induced asthma and the expressions of TRPA1 and tight junctions in mice. Mol Immunol. 2021;135:62-72. DOI: 10.1016/j.molimm.2021.04.006.
  24. Wu CC, Hsu TY, Chang JC, Ou CY, Kuo HC, Liu CA, et al. Paternal tobacco smoke correlated to offspring asthma and prenatal epigenetic programming. Front Genet. 2019;10:471. DOI: 10.3389/fgene.2019.00471.
  25. Lu K, Lai KP, Stoeger T, Ji S, Lin Z, Lin X, et al. Detrimental effects of microplastic exposure on normal and asthmatic pulmonary physiology. J Hazard Mater. 2021;416:126069. DOI: 10.1016/j.jhazmat.2021.126069.
  26. Sly PD, Kusel M, Holt PG. Do early-life viral infections cause asthma? J Allergy Clin Immunol. 2010;125(6):1202-5. DOI: 10.1016/j. jaci.2010.01. 024.
  27. Mackenzie KJ, Anderton SM, Schwarze J. Viral respiratory tract infections and asthma in early life: cause and effect? Clin Exp Allergy. 2014;44(1):9-19. DOI: 10.1111/cea.12246.
  28. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-75. DOI: 10.1002/hep.28356.
  29. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-45. DOI: 10.1016/j.cell.2016.05.041.
  30. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619-25. DOI: 10.3945/jn.109.104638.
  31. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141(5):769-76. DOI: 10.3945/jn.110. 135657.
  32. Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res. 2015;13(1):11-8. DOI: 10.5217/ir. 2015.13.1.11.
  33. Niewiem M, Grzybowska-Chlebowczyk U. Intestinal barrier permeability in allergic diseases. Nutrients. 2022;14(9):1893. DOI: 10.3390/ nu14091893.
  34. Heinemann U, Schuetz A. Structural features of tight-junction proteins. Int J Mol Sci. 2019;20(23):6020. DOI: 10.3390/ijms20236020.
  35. Buckley A, Turner JR. Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb Perspect Biol. 2018;10(1):a029314. DOI: 10.1101/cshperspect.a029314.
  36. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836-46. DOI: 10.1002/hep.24001.
  37. Pivtorak KV. Osoblyvosti farmakoterapii NAZHP u khvorykh z nadlysokovoiu masoiu tila ta ozhyrinniam. Zaporizkyi Medychnyi Zhurnal. 2017;19(4):520-4. [in Ukrainian].
  38. Carlier FM, de Fays C, Pilette C. Epithelial barrier dysfunction in chronic respiratory diseases. Front Physiol. 2021;12:691227. DOI: 10.3389/fphys. 2021.691227.
  39.  Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-73. DOI: 10.1001/jama.2015.5370. Erratum in: JAMA. 2015;314(14):1521. DOI: 10.1001/jama.2015.12071.
  40. Yang Z, Mao W, Wang J, Yin L. The gut-lung axis in asthma: microbiota-driven mechanisms and therapeutic perspectives. Front Microbiol. 2025;16:1680521. DOI: 10.3389/fmicb.2025.1680521.
  41. Parrón-Ballesteros J, Gordo RG, López-Rodríguez JC, Olmo N, Villalba M, Batanero E, et al. Beyond allergic progression: from molecules to microbes as barrier modulators in the gut-lung axis functionality. Front Allergy. 2023;4:1093800. DOI: 10.3389/falgy.2023.1093800.
  42. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-78. DOI: 10.1053/j. gastro.2015.04.005.

Publication of the article:

«Bulletin of problems biology and medicine», 2026 Issue 1, 180, 95-103 pages, index UDC 616.24-002-036.12:616.36-003.826:612.017

DOI:

10.29254/2077-4214-2026-1-180-95-103

2026 Issue 1, 180
bronchial asthma COPD epithelial permeability MASLD microbiota
29.03.2026
Was this article helpful?
0
0

Leave a Reply

Your email address will not be published. Required fields are marked *


The reCAPTCHA verification period has expired. Please reload the page.